Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.19.8215

Prognostic Significance of Expression of CD133 and Ki-67 in Gastric Cancer  

Saricanbaz, Irem (Department of Radiation Oncology, Konya Training and Research Hospital)
Karahacioglu, Eray (Department of Radiation Oncology, Faculty of Medicine, University of Gazi)
Ekinci, Ozgur (Department of Pathology, Faculty of Medicine, University of Gazi)
Bora, Huseyin (Department of Radiation Oncology, Faculty of Medicine, University of Gazi)
Kilic, Diclehan (Department of Radiation Oncology, Faculty of Medicine, University of Gazi)
Akmansu, Muge (Department of Radiation Oncology, Faculty of Medicine, University of Gazi)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.19, 2014 , pp. 8215-8219 More about this Journal
Abstract
CD133 is one of the most important stem cell markers in solid cancers and Ki-67 is a marker that reflects cell proliferation. The relationships between the expression of CD133 and Ki-67 and prognosis in gastric carcinoma are unknown and need exploring. We examined 50 gastric cancer patients retrospectively in the Radiation Oncology Department of the Faculty of Medicine, Gazi University. CD133 and Ki-67 expression was examined using immunohistochemical staining. The survival rate in patients with CD133 positive expression was significantly worse than that in the patients with negative expression (p=0.04). Expression of CD133 had a positive correlation with that of Ki-67 (r=0.350; p=0.014). Multivariate analysis revealed that the expression of CD133 was an independent prognostic factor in gastric cancer (p=0.02). Conclusion, expression of CD133 may be a useful prognostic marker in gastric cancer.
Keywords
CD133; Ki-67; gastric cancer; cancer stem cell; prognosis;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Maeda S, Shinchi H, Kurahara H, et al (2008). CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer, 98, 1389-97.   DOI
2 Lazar D, Taban S, Sporea I et al (2010). Ki-67 expression in gastric cancer. Results from a prospective study with longterm follow-up. Rom J Morphol Embryol, 51, 655-61.
3 Lee HE, Kim MA, Lee BL, Kim WH (2010). Low Ki-67 proliferation index is an indicator of poor prognosis in gastric cancer. J Surg Oncol, 102, 201-6.   DOI   ScienceOn
4 Lee HH, Seo KJ, An CH, Kim JS, Jeon HM (2012). CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer. J Surg Oncol, 106, 999-1004.   DOI
5 Li C, Heidt DG, Dalerba P, et al (2007). Identification of pancreatic cancer stem cells. Cancer Res, 67, 1030-7.   DOI   ScienceOn
6 Neuzil J, Stantic M, Zobalova R, et al (2007). Tumour-initiating cellsvs. cancer 'stem' cells and CD133: what' s the name? Biochem Biophys Res Commun, 355, 855-9.   DOI
7 O' Brien CA, Kreso A, Dick JE (2009). Cancer stem cells in solid tumors: An Overview. Seminars Rad Oncology, 19, 71-7.
8 Reya T, Morrison SJ, Clarke MF, Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105-11.   DOI   ScienceOn
9 Ross W, Hall PA (1995). Ki67: from antibody to molecule to understanding? J Clin Pathol: Mol Pathol, 48, 113-7.   DOI
10 Sanaat Z, Halimi M, Ghojezadeh M, et al (2013). Immunohistochemical analysis of p53, Ki-67, CD44, HER-2/neu expression patterns in gastric cancer, and their associatin with one year survival in North-West of Iran. Int J Hematol Oncol Stem Cell Res, 7, 15-20.
11 Smith LM, Nestevora A, Ryan MC, et al (2008). CD133/prominin-1 is a potential therapeutic target for antibodydrug conjugates in hepatocellular and gastric cancers. Br J Cancer, 99, 100-9.   DOI   ScienceOn
12 Satpute PS, Hazarey V, Ahmed R, Yadav L (2013). Cancer stem cells in head and neck squmous cell carcinoma: a review. Asian Pac J Cancer Prev, 14, 5579-87.   DOI
13 Scholzen T, Gerdes J (2000). The Ki-67 protein: From the known and the unknown. J Cell Physiol, 182, 311-22.   DOI   ScienceOn
14 Setoguchi T, Taga T, Kondo T (2004). Cancer stem cells persist in many cancer cell lines. Cell Cycle, 3, 414-5.   DOI
15 Tabarestani S, Ghafouri-Fard S (2012). Cancer stem cells and response to therapy. Asian Pac J Cancer Prev, 13, 5947-54.   DOI   ScienceOn
16 Tang C, Ang BT, Pervaiz S (2007). Cancer stem cell: target for anti-cancer therapy. FASEB J, 21, 3777-85.   DOI   ScienceOn
17 Turkish Public Health Organization (2009). Web address: http://kanser.gov.tr/daire-faaliyetleri/kanser-istatistikleri.html
18 Yu JW, Zhang P, Wu JG, et al (2010). Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocarcinoma. J of Experimental and Clinic Cancer Resarch, 7, 29-141.
19 Yang X, Wang F, Chen C, et al (2011). High Ki-67 expression is a poor prognostic indicator of 5-year survival in patients with invasive breast cancer. Asian Pac J Cancer Prev, 12, 3101-4.
20 Yao Q, Sun J, Ma H, et al (2014) Monitoring microRNAs using a molecular beacon in CD133+/CD338+ human lung adenocarcinoma-initiating A549 cells. Asian Pac J Cancer Prev, 15, 161-6.   DOI   ScienceOn
21 Yu JW, Wang SL, Wu JG, et al (2014). Study on the biological characteristics of CD133 (+) cells interfered by RNA interference in gastric cancer. ISRN Gastroenterol, 19, 329519.
22 Zhao P, Lu Y, Jiang X, Li X (2011). Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci, 102, 1107-11.   DOI
23 Weidner N, Moore DH 2nd, Vartanian R (1994). Correlation of Ki-67 antijen expression with mitotic Figure index and tumor grade in breast carcinomas using the novel 'paraffin' reactive MIBI antibody. Hum Pathol, 25, 337-42.   DOI   ScienceOn
24 Wen L, Chen X,Yang K, et al (2013). Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: A systematic Review. PLoS ONE, 8, 59154.   DOI
25 Zhao P, Li Y, Lu Y (2010). Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer, 10, 218.   DOI
26 Zeppernick F, Ahmadi R, Campos B, et al (2008). Stem cell marker CD133 affects clinical outcome in gloma patients. Clin Cancer Res, 14, 123-9.   DOI
27 Baba T, Convery P, Matsumura N, et al (2009). Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene, 28, 209-18.   DOI   ScienceOn
28 Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res, 65, 10946-51.   DOI   ScienceOn
29 Al Hajj M (2007). Cancer stem cells and oncology therapeutics. Curr Opin Oncol, 19, 61-4.
30 Arciero CA (2010). Ki-67 proliferation index and gastric cancer: Answers or More Questions. J Surg Onco, 102, 199-200.   DOI
31 Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer incidence and Mortality worldwide: IARC Cancer Base No.11 (Internet). Web address: http://globocan.iarc.fr
32 Hashimato K, Aoyagi K, Isobe T, Kouhuji K, Shirouzu K (2014). Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Gastric Cancer, 17, 97-106.   DOI
33 He WL, Li YH, Yang DJ, et al (2013). Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patient with gastric carcinoma. Eur J Surg Oncol, 39, 141-9.   DOI
34 Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2008). CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer, 99, 1285-9.   DOI
35 Jordan CT, Guzman ML, Noble M (2006). Cancer stem cells. N Engl J Med, 355, 1253-61.   DOI   ScienceOn
36 Ishigami S, Uenu S, Arigami T, et al (2010). Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res, 30, 2453-7.
37 Jiang Y, He Y, Li H et al (2012). Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Gastric Cancer, 15, 440-50.   DOI